Following the FDA's complete response letter for the drug, Eli Lilly has begun preparing a proposed risk evaluation mitigation strategy for Zyprexa Adhera. After the regulator's previous non-approval letter requesting more information regarding adverse effects in clinical trials, this further delay plays into the hands of Johnson & Johnson's direct competitor product paliperidone palmitate.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions